BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25611435)

  • 1. Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor.
    Porakishvili N; Vispute K; Steele AJ; Rajakaruna N; Kulikova N; Tsertsvadze T; Nathwani A; Damle RN; Clark EA; Rai KR; Chiorazzi N; Lydyard PM
    Mol Med; 2015 Apr; 21(1):46-57. PubMed ID: 25611435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells.
    Porakishvili N; Memon A; Vispute K; Kulikova N; Clark EA; Rai KR; Nathwani A; Damle RN; Chiorazzi N; Lydyard PM
    Br J Haematol; 2011 May; 153(4):486-98. PubMed ID: 21443749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
    Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
    PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of the expression of CD32 and CD180 receptors on CLL cells and MEC1 cell line.
    Tsertsvadze T; Mitskevich N; Ghirdaladze D; Porakishvili N
    Georgian Med News; 2015 Mar; (240):56-9. PubMed ID: 25879560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.
    You M; Dong G; Li F; Ma F; Ren J; Xu Y; Yue H; Tang R; Ren D; Hou Y
    Cell Mol Immunol; 2017 Feb; 14(2):192-202. PubMed ID: 26277892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells.
    Shcherbina V; Gordiienko I; Shlapatska L; Gluzman D; Sidorenko S
    Neoplasma; 2021 Jul; 68(4):760-769. PubMed ID: 33904315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
    Kakodkar P; More S; András K; Papakonstantinou N; Kelly S; Makrooni MA; Ortutay C; Szegezdi E
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD150 and CD180 are involved in regulation of transcription factors expression in chronic lymphocytic leukemia cells.
    Gordiienko I; Shlapatska L; Kholodniuk VM; Kovalevska L; Ivanivskaya TS; Sidorenko SP
    Exp Oncol; 2017 Dec; 39(4):291-298. PubMed ID: 29284783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different expression of CD180, CD284 and CD14 receptors on the CD19+ subpopulation of normal and B-CLL lymphocytes.
    Antosz H; Sajewicz J; Marzec-Kotarska B; Kocki J; Dmoszyńska A
    Folia Histochem Cytobiol; 2009; 47(4):593-8. PubMed ID: 20430725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.
    Kawauchi K; Ogasawara T; Yasuyama M
    Int J Hematol; 2002 Jun; 75(5):508-13. PubMed ID: 12095152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHAGOCYTOSIS AND EXPRESSION OF FCg-RECEPTORS AND CD180 ON MONOCYTES IN CHRONIC LYMPHOCYTIC LEUKEMIA.
    Tsertsvadze T; Mitskevich N; Bilanishvili A; Girdaladze D; Porakishvili N
    Georgian Med News; 2017 Sep; (270):88-93. PubMed ID: 28972490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
    Krysov S; Steele AJ; Coelho V; Linley A; Sanchez Hidalgo M; Carter M; Potter KN; Kennedy B; Duncombe AS; Ashton-Key M; Forconi F; Stevenson FK; Packham G
    Blood; 2014 Nov; 124(20):3101-9. PubMed ID: 25170122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.